Assessing the Clinical Efficacy of a Virtual Reality Tool for the Treatment of Obesity: Randomized Controlled Trial.

Paula Garcia-Royo, Elena Álvarez de la Campa, Dimitra Anastasiadou, Bernhard Spanlang, Julia Vázquez-De Sebastián, Marta Comas, Mel Slater, Pilar Lusilla-Palacios, Josep Antoni Ramos-Quiroga, Pol Herrero, Andreea Ciudin

Journal: Journal of medical Internet research 2024;26():e51558

PMID: 38578667

Abstract

BACKGROUND

Virtual reality (VR) interventions, based on cognitive behavioral therapy principles, have been proven effective as complementary tools in managing obesity and have been associated with promoting healthy behaviors and addressing body image concerns. However, they have not fully addressed certain underlying causes of obesity, such as a lack of motivation to change, low self-efficacy, and the impact of weight stigma interiorization, which often impede treatment adherence and long-term lifestyle habit changes. To tackle these concerns, this study introduces the VR self-counseling paradigm, which incorporates embodiment and body-swapping techniques, along with motivational strategies, to help people living with obesity effectively address some of the root causes of their condition.

OBJECTIVE

This study aims to assess the clinical efficacy of ConVRself (Virtual Reality self-talk), a VR platform that allows participants to engage in motivational self-conversations.

METHODS

A randomized controlled trial was conducted with 68 participants from the bariatric surgery waiting list from the obesity unit of the Vall d'Hebron University Hospital in Barcelona, Spain. Participants were assigned to 1 of 3 groups: a control group (CG), which only received treatment as usual from the obesity unit; experimental group 1 (EG1), which, after intensive motivational interviewing training, engaged in 4 sessions of VR-based self-conversations with ConVRself, and underwent embodiment and body-swapping techniques; and experimental group 2 (EG2), which engaged in 4 VR-based sessions led by a virtual counselor with a prerecorded discourse, and only underwent the embodiment technique. In the case of both EG1 and EG2, the VR interventions were assisted by a clinical researcher. Readiness to change habits, eating habits, and psychological variables, as well as adherence and satisfaction with ConVRself were measured at baseline, after the intervention, 1 week after the intervention, and 4 weeks after the intervention.

RESULTS

Regarding the primary outcomes, EG1 (24/68, 35%) and EG2 (22/68, 32%) showed significant improvements in confidence to lose weight compared to the CG (22/68, 32%) at all assessment points (β=-.16; P=.02). Similarly, EG1 demonstrated a significant increase after the intervention in readiness to exercise more compared to the CG (β=-.17; P=.03). Regarding the secondary outcomes, EG1 participants showed a significant reduction in uncontrolled eating (β=.71; P=.01) and emotional eating (β=.29; P=.03) compared to the CG participants, as well as in their anxiety levels compared to EG2 and CG participants (β=.65; P=.01). In addition, participants from the experimental groups reported high adherence and satisfaction with the VR platform (EG1: mean 59.82, SD 4.00; EG2: mean 58.43, SD 5.22; d=0.30, 95% CI -0.30 to 0.89).

CONCLUSIONS

This study revealed that using VR self-conversations, based on motivational interviewing principles, may have benefits in helping people with obesity to enhance their readiness to change habits and self-efficacy, as well as reduce dysfunctional eating behaviors and anxiety.

TRIAL REGISTRATION

ClinicalTrials.gov NCT05094557; https://www.clinicaltrials.gov/study/NCT05094557.

©Dimitra Anastasiadou, Pol Herrero, Paula Garcia-Royo, Julia Vázquez-De Sebastián, Mel Slater, Bernhard Spanlang, Elena Álvarez de la Campa, Andreea Ciudin, Marta Comas, Josep Antoni Ramos-Quiroga, Pilar Lusilla-Palacios. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 05.04.2024.

Address: Department of Clinical and Health Psychology, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.; Psychiatry, Mental Health and Addictions Research Group, Vall d´Hebron Research Institute, Barcelona, Spain.; Psychiatry, Mental Health and Addictions Research Group, Vall d´Hebron Research Institute, Barcelona, Spain.; Psychiatry, Mental Health and Addictions Research Group, Vall d´Hebron Research Institute, Barcelona, Spain.; RE-FiT Barcelona Research Group, Vall d'Hebron Research Institute & Parc Sanitari Pere Virgili, Barcelona, Spain.; Virtual Bodyworks S.L., Barcelona, Spain.; The Institute of Neurosciences, Universitat de Barcelona, Barcelona, Spain.; Department of Clinical Psychology and Psychobiology, Universitat de Barcelona, Barcelona, Spain.; Virtual Bodyworks S.L., Barcelona, Spain.; Endocrinology and Nutrition Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain.; Psychiatry, Mental Health and Addictions Research Group, Vall d´Hebron Research Institute, Barcelona, Spain.; Psychiatry Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.; Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.